falipamil

bradycardic agent which blocks myocardial calcium channels in frequency- & voltage-dependent manner; RN given refers to parent cpd; structure given in Unlisted Drugs

Also Known As:

5,6-dimethoxy-2-(3-((alpha-(3,4-dimethoxy)phenylethyl)methylamino)propyl)phthalimidine; AQ-A 39; AQ-A-39; AQ-AH 208; AQ-AH-208; AQA 39; AQA 39Cl; falipamil hydrochloride; 1H-Isoindol-1-one, 2-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-2,3-dihydro-5,6-dimethoxy-

Networked: 19 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Heart Diseases (Heart Disease) 12/01/1987 - "The results suggest that AQ-A 39 will be useful in the short term management of patients with ischaemic heart disease." 01/01/1981 - "AQ-A 39 induces cardiovascular actions which might be of benefit in the treatment of ischaemic heart disease." 12/01/1987 - "Comparison of AQ-A 39 with propanolol and placebo in ischaemic heart disease." 12/01/1987 - "Thus falipamil can be used to normalize sinus rate in patients with sinus tachycardia of various origin, particularly in intensive care, in acute ischaemic heart disease, in anaesthesia and in surgery cases." 12/01/1987 - "In a randomized, controlled study 10 male patients with angiographically confirmed ischaemic heart disease received AQ-A 39 (falipamil), a heart rate reducing agent in a single intravenous dose (2 mg kg-1) in comparison to propranolol (0.1 mg kg-1). "
2.	Bradycardia 07/01/1987 - "Effect of the new specific bradycardia agent AQ-A39 (falipamil) on coronary collateral blood flow in dogs." 01/01/1986 - "[Electrophysiologic and hemodynamic effects of the new bradycardia-inducing substance AQ-A 39]." 08/01/1986 - "Thus, the beneficial actions of AQ-A39 and AQ-AH 208 on improving the recovery of subendocardial contractile function (% SS) may be explained partially by a reduction in myocardial oxygen requirements as a result of bradycardia. " 01/01/1985 - "In nonischemic myocardium, AQ-AH 208 did not change transmural blood flow in spite of the bradycardia, whereas UL-FS 49 decreased flow. " 09/03/1984 - "In comparable experiments AQ-A 39 was much less effective, the EC30 for the negative chronotropic effect being 0.61 microgram/ml. In rabbit aortic strips in the presence of 43 mM K+ and 1.8 mM Ca2+, UL-FS 49 relaxed contraction by 30% at 15 micrograms/ml. In contrast to UL-FS 49, several "Ca2+-antagonists" elicited aortic relaxation at lower concentrations than bradycardia. "
3.	Myocardial Ischemia (Ischemic Heart Diseases) 07/01/1989 - "These results suggest that falipamil decreases HR at exercise in normal subjects and may exert antianginal effects in patients with myocardial ischemia." 01/01/1986 - "AQ-A 39 appears to be suitable to reduce inadaequate increases in sinus rate, and seems to be of particular interest in surgical cases or intensive care emergencies as well as in acute ischemic heart disease." 09/01/1985 - "Effects of AQ-AH 208, a new specific bradycardic agent, on myocardial ischemia-reperfusion injury in anesthetized dogs."
4.	Sinus Tachycardia 05/01/1990 - "Falipamil (2-[3-[3-(3,4-dimethoxyphenetylmethylamino]propyl]-5,6- dimethoxyphthalamidine; 1) is a new specific bradycardic agent for the treatment of sinus tachycardia. " 11/01/1987 - "The haemodynamic responses after application of 100-200 mg falipamil (5,6-dimethoxy-2-(3-((alpha (3,4-dimethoxy)-phenylethyl) methylamino)propyl)phthalimidine, AQ-A 39) a new calcium channel blocker with specific action on the sinus node, was studied in 11 patients with perioperative sinus tachycardia (greater than 120/min). " 12/01/1987 - "Thus falipamil can be used to normalize sinus rate in patients with sinus tachycardia of various origin, particularly in intensive care, in acute ischaemic heart disease, in anaesthesia and in surgery cases." 11/01/1987 - "[Therapy of perioperative sinus tachycardia with the new calcium antagonist falipamil]." 11/01/1987 - "Falipamil may become a valuable drug for the therapy of sinus tachycardia due to catecholamines during the perioperative period."
5.	Tachycardia (Tachyarrhythmias) 09/01/1993 - "In a separate group of 10 dogs with inducible SVT, AQ-A 39 (4 mg/kg i.v.) abolished elicitation of tachycardia in 3 dogs and decreased its rate in 6 other dogs. " 10/01/1990 - "Falipamil, on the circulation controlling excessive intraoperative tachycardia. " 03/01/1983 - "AQ-A 39 prevented the tachycardia by both slowing of AV nodal conduction and by prolongation of action potential duration in the AV nodal and atrial compartments of the reentrant circuit associated with the appearance of different gap phenomena of the AV conduction. "

Related Drugs and Biologics

1.	falipamil
2.	Reducing Agents
3.	Propranolol (Inderal)
4.	Calcium
5.	zatebradine
6.	phthalimidine
7.	Cholinergic Agents (Cholinergics)
8.	Yohimbine (Yocon)
9.	Verapamil (Calan)
10.	Adrenergic Receptors (Adrenergic Receptor)

Related Therapies and Procedures

1.	Critical Care (Surgical Intensive Care)
2.	Perioperative Period
3.	Therapeutics
4.	Microspheres (Microsphere)
5.	Ligation